HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $50 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Amylyx Pharma (NASDAQ:AMLX) and maintained a $50 price target.
August 11, 2023 | 4:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amylyx Pharma's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $50 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a $50 price target by HC Wainwright & Co. indicates their confidence in Amylyx Pharma's potential, which could positively impact the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100